Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$75.94 USD
+1.14 (1.52%)
Updated May 6, 2024 04:00 PM ET
After-Market: $76.09 +0.15 (0.20%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
AXSM 75.94 +1.14(1.52%)
Will AXSM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for AXSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AXSM
Should You Buy Axsome Therapeutics (AXSM) Ahead of Earnings?
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
AXSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline
Alkermes' (ALKS) ALKS 2680 Betters Wakefulness in Phase Ib Study
Other News for AXSM
AXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024
Axsome Therapeutics, Inc. (AXSM) Q1 2024 Earnings Call Transcript
Axsome Therapeutics price target lowered by $2 at Citi, here's why
Fly Intel: Pre-market Movers
Buy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion Potential